Skip to content
Catalyst

knowcompoundstrehalose

Specimen compound

Trehalose

fig. 1Trehalose · findings by direction and evidence strength

↑ raised 1 finding in 1 endpoint · ↓ lowered 1 in 1 · – no difference found 4 in 4

01 · the evidence, ordered

What the evidence says

Strong
0
Moderate
4
Limited
0
Very limited
2
Insufficient
0

How to read these marks

Fig. 2 Trehalose CHEBI:27082 6 endpoints 6 findings
×1.60
Labels
CompoundInspector

Trehalose

Most findings

  • C-reactive protein concentration×1
  • Flow-mediated dilation×1
  • Interleukin-6 concentration×1
  • Tumour necrosis factor alpha concentration×1
  • Mean power output×1
  • Peak postprandial blood glucose×1

36 compounds on the outer ring, not drawn

Keys

← → round a ring↑ ↓ out and inEnter selecte the outer ringf fit to view+ − zoomEsc clearclick a node to select it

  1. C-reactive protein concentration
  2. Flow-mediated dilation
  3. Interleukin-6 concentration
  4. Tumour necrosis factor alpha concentration
  5. Mean power output
  6. Peak postprandial blood glucose
fig. 3 · 6 endpoints · 6 findingsno endpoint contested

02 · findings

What trehalose moved, and by how much

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  • Industry funding: named on its row.
Direction
Strength, at least

6 shown

  1. C-reactive protein concentrationMoved: no difference foundEvidence: ModeratePaper: PMID 272084152016
    Who
    Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers; comparator maltose 100 g/day, an isocaloric disaccharide
    Dose studied
    100 g/day trehalose dissolved in 12 ounces of water, 12 weeks

    There were no baseline group differences in oxidized LDL, CRP, IL-6 or TNF-α and these factors did not change differentially across the intervention period in the maltose and trehalose treated groups (all P>0.1, Table 4).”

    Quoted verbatim from Oral trehalose supplementation improves resistance artery endothelial function in healthy middle-aged and older adults.RCT · 3 monthsPermalink
  2. Flow-mediated dilationMoved: no difference foundEvidence: ModeratePaper: PMID 272084152016
    Who
    Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers (trehalose 15, maltose 17); comparator maltose 100 g/day, an isocaloric disaccharide
    Dose studied
    100 g/day trehalose dissolved in 12 ounces of water, 12 weeks

    FMD did not change differentially across the intervention in the trehalose and maltose treated groups when FMD was expressed as either percent or absolute change (both P>0.1, Figure 6).”

    Quoted verbatim from Oral trehalose supplementation improves resistance artery endothelial function in healthy middle-aged and older adults.RCT · 3 monthsPermalink
  3. Interleukin-6 concentrationMoved: no difference foundEvidence: ModeratePaper: PMID 272084152016
    Who
    Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers; comparator maltose 100 g/day, an isocaloric disaccharide
    Dose studied
    100 g/day trehalose dissolved in 12 ounces of water, 12 weeks

    There were no baseline group differences in oxidized LDL, CRP, IL-6 or TNF-α and these factors did not change differentially across the intervention period in the maltose and trehalose treated groups (all P>0.1, Table 4).”

    Quoted verbatim from Oral trehalose supplementation improves resistance artery endothelial function in healthy middle-aged and older adults.RCT · 3 monthsPermalink
  4. Tumour necrosis factor alpha concentrationMoved: no difference foundEvidence: ModeratePaper: PMID 272084152016
    Who
    Non-smoking men and postmenopausal women aged 50-77 years free of clinical disease, all randomized completers; comparator maltose 100 g/day, an isocaloric disaccharide
    Dose studied
    100 g/day trehalose dissolved in 12 ounces of water, 12 weeks

    There were no baseline group differences in oxidized LDL, CRP, IL-6 or TNF-α and these factors did not change differentially across the intervention period in the maltose and trehalose treated groups (all P>0.1, Table 4).”

    Quoted verbatim from Oral trehalose supplementation improves resistance artery endothelial function in healthy middle-aged and older adults.RCT · 3 monthsPermalink
  5. Peak postprandial blood glucoseMoved: lowersEvidence: Very limitedPaper: PMID 196642962009
    Who
    Ten overweight subjects; comparator is an equal carbohydrate load of glucose, not a non-sugar control; peak glucose after the carbohydrate drink taken with a standardised mixed meal, sampled every 30 min for 3 h · n = 10
    Dose studied
    75 g carbohydrate equivalents of trehalose as a drink after an overnight fast, and a mixed meal with 25 percent of energy as trehalose at 12.30 hours; each given once per session

    Ingestion of carbohydrates with a mixed meal resulted in a lower peak glucose response and a lower change in area under the curve (DeltaAUC) following trehalose when compared with glucose.”

    Quoted verbatim from Reduced glycaemic and insulinaemic responses following trehalose ingestion: implications for postprandial substrate use.crossoverPermalink
  6. Mean power outputMoved: raisesEvidence: Very limitedPaper: PMID 355657442022Industry funded
    Who
    Experiment 1: 12 healthy recreationally trained young men, fasted 12 h, ingesting 500 mL of the drink after the first of four sets of Wingate tests during about 5 h of intermittent cycling; fourth set only; comparator is 8% glucose solution · n = 12
    Dose studied
    500 mL of 8% trehalose (40 g) solution, single drink within 5 min after the first Wingate set

    In the fourth set, the mean power value was significantly higher for T8 (93.3 ± 5.8%) than G8 (88.9 ± 7.2%) (p < 0.05, d = 0.68), thus reproducing the results of the previous study.”

    Quoted verbatim from Effects of Trehalose Solutions at Different Concentrations on High-Intensity Intermittent Exercise Performance.crossoverPermalink

No dose is advised.

  • Dose studied: as its paper gave it.
  • Evidence strength: computed from the study. How it is computed
  • Industry funding: named on its row.

03 · on the label · 41 products

Labelled products

Source: NIH DSLD · Ingredient: trehalose · 41 products · Declared amount per serving: 1,250–3,500 mg

6 labels state an amount35 do not

  • D'Adamo Personalized NutritionTrehalose Complex3,100 mgper 1 tspDSLD:27250
  • Gaspari NutritionGaspari's Real Mass Chocolate Ice Creamamount not statedper 3 scoopsDSLD:2043
  • Gaspari NutritionGaspari's Real Mass Rich Vanilla Milkshakeamount not statedper 150 gDSLD:2044
  • Gaspari NutritionGaspari's Real Mass Strawberry Milkshakeamount not statedper 150 gDSLD:2045
  • Gaspari NutritionSizeOn Grape Cooleramount not statedper 68 gDSLD:228126
  • Gaspari NutritionSizeOn Grape Cooleramount not statedper 68 gDSLD:322587
  • Gaspari NutritionSizeOn Lemon Iceamount not statedper 68 gDSLD:322588
  • Gaspari NutritionSizeOn Orange Cooleramount not statedper 66 gDSLD:2047
  • Gaspari NutritionSizeOn Orange Cooleramount not statedper 68 gDSLD:228114
  • Gaspari NutritionSizeOn Wildberry Punchamount not statedper 68 gDSLD:228121
  • MMUSAATP+ For Her Strawberryamount not statedper 5 mLDSLD:308316
  • MMUSAATP+ Strawberryamount not statedper 1 mLDSLD:308315
Show the remaining 29Show the first 12

Label record: NIH Office of Dietary Supplements · CC0

04 · the record

Sources

15

papers screened for trehalose

admitted
3
read and discarded
9
not read yet
3

The screening record, every paper and why

Documented interactions
None reported

Sources cited

3 papers · 6 findings

Show every paper citedHide the papers cited
46Endpoints measured, not recorded as findingsEvery row, on one page